Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress

Title: Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress

Volume: 6 Issue: 3

Author(s): Antiopi Voultsiadou and Vasiliki Sarli

Affiliation:

Keywords: Antimitotics, Ispinesib, KSP kinesin, Mitotic kinesins, Neoplasms, Taxanes, Tubulin-targeting Agents, vinca alkaloids, paclitaxel

Abstract: Antimitotic chemotherapy remains the most effective approach to treat a variety of human neoplasms. Since the discovery of tubulin-targeting agents, vinca alkaloids and the taxanes including paclitaxel and docetaxel are used clinically to treat several solid tumors of the head and neck, breast, lung, ovary, and bladder. Despite the preclinical and clinical success of tubulin-targeting agents, the ability of tumors to develop an acquired resistance to drugs used for treatment and neurotoxicity severely limited their long-term effectiveness to cancer cure. Lately, advances in antimitotic treatments led to the identification of novel mitosis-specific agents that are expected to show higher selectivity and less cytotoxicity compared to known antimitotics. This review focuses on the progress of kinesin motor inhibitors that target proteins that function predominantly in mitosis.

Cite this article as:

Voultsiadou Antiopi and Sarli Vasiliki, Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress, Reviews on Recent Clinical Trials 2011; 6 (3) . https://dx.doi.org/10.2174/157488711796575522